drugset / Trial / NCT02495844

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

NCT02495844

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.

Timeline

Start
2015-07
Primary completion
2017-02
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Padsevonil Small molecule 100 mg Oral
Subject Padsevonil Small molecule 200 mg Oral

Indications